GlassScriptPhysician profile
David R Duhamel
NPI 1609869932
$17,572.36
in general payments reported to CMS, 2019-2025
27 companies · $2,890 in 2025
The $2,890 reported for 2025 was more than what 89% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,819 · 2020: $34.64 · 2021: $340 · 2022: $5,188 · 2023: $1,183 · 2024: $117 · 2025: $2,890.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,178 · Food and Beverage: $2,012.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,178.36 |
| Food and Beverage | $2,011.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $5,261.92 | 2019-2022 | |
| Cook Incorporated | $4,400.00 | 2019 | |
| Pulmonx Corporation | $3,050.30 | 2019 | |
| Medical Device Business Services, INC. | $2,422.48 | 2025 | Monarch |
| Noah Medical Corporation | $1,055.00 | 2023-2025 | Galaxy |
| Astrazeneca Pharmaceuticals LP | $349.32 | 2019-2025 | Breztri, Fasenra |
| Glaxosmithkline, LLC. | $310.09 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genentech USA, INC. | $125.00 | 2019 | |
| Genzyme Corporation | $111.38 | 2021-2022 | |
| Shionogi INC | $84.18 | 2024-2025 | Fetroja |
| United Therapeutics Corporation | $59.46 | 2023 | Tyvaso |
| Takeda Pharmaceuticals U.S.A., INC. | $42.80 | 2025 | Glassia |
| Cook Medical LLC | $36.61 | 2019-2020 | |
| Insmed, INC. | $27.24 | 2025 | Arikayce |
| Jazz Pharmaceuticals INC. | $23.50 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pinnacle Biologics, INC | $23.41 | 2021 | |
| Grifols USA, LLC | $21.84 | 2025 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $19.70 | 2019 | |
| Viatris Specialty LLC | $19.62 | 2025 | Yupelri |
| Bard Access Systems, INC. | $19.27 | 2019 | |
| Electromed, INC. | $18.93 | 2025 | Smartvest |
| Philips North America LLC | $18.39 | 2022 | |
| Covidien LP | $17.83 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $15.51 | 2019 | |
| Idorsia Pharmaceuticals US INC | $14.46 | 2024 | Quviviq |
| Galderma Laboratories, L.P. | $12.93 | 2023 | |
| Ambu INC. | $11.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Duhamel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.